STRENSIQ Solution for Injection
asfotase alfa
40 mg/ml
Alexion Pharma International Operations Unlimited Company
| Pack size | 12 Vial (0.7 ml) |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 7774.88 AED |
Available as:
Indications
STRENSIQ Solution for Injection is used for:
Indicated for the treatment of patients with perinatal/infantile and juvenile onset hypophosphatasia (HPP).
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of asfotase alfa :
Mechanism of Action
HPP is caused by a deficiency in TNSALP (tissue non-specific alkaline phosphatase) enzyme activity, which leads to elevations in several TNSALP substrates, including inorganic pyrophosphate (PPi). Elevated extracellular levels of PPi block hydroxyapatite crystal growth which inhibits bone mineralization and causes an accumulation of unmineralized bone matrix which manifests as rickets and bone deformation in infants and children and as osteomalacia (softening of bones) once growth plates close, along with muscle weakness. Replacement of the TNSALP enzyme upon Asfotase alfa treatment reduces the enzyme substrate levels.
Note
STRENSIQ 40 mg/ml Solution for Injection manufactured by Alexion Pharma International Operations Unlimited Company. Its generic name is asfotase alfa. STRENSIQ is availble in Saudi Arabia.
Farmaco SA drug index information on STRENSIQ Solution for Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.